Bissett, Cameron
Belij-Rammerstorfer, Sandra
Ulaszewska, Marta
Smith, Holly
Kailath, Reshma
Morris, Susan
Powers, Claire
Sebastian, Sarah
Sharpe, Hannah R. http://orcid.org/0000-0002-1194-2429
Allen, Elizabeth R.
Wang, Ziyin http://orcid.org/0000-0002-1110-808X
Cunliffe, Robert F.
Sallah, Hadijatou J.
Spencer, Alexandra J. http://orcid.org/0000-0001-7958-6961
Gilbert, Sarah http://orcid.org/0000-0002-6823-9750
Tregoning, John S. http://orcid.org/0000-0001-8093-8741
Lambe, Teresa
Funding for this research was provided by:
RCUK | Medical Research Council (MC_PC_18059)
Article History
Received: 25 January 2024
Accepted: 14 June 2024
First Online: 26 June 2024
Competing interests
: The authors of this manuscript have the following competing interests: S.G. is the co-founder and a board member of Barinthus Biotherapeutics (formerly Vaccitech), and is named as an inventor on patents covering the use of ChAdOx1 vector vaccines. T.L. was a consultant to Barinthus Biotherapeutics on an unrelated project involving ChAdOx1 vector vaccines. She is also named as an inventor on a patent involving unrelated ChAdOx1 vector vaccines. T.L. also reports an honorarium from Seqirus. S.S. is senior director of research at Barinthus Biotherapeutics. All other authors declare no competing interests.